Urine and serum samples collected from four standard-bred mares after an oral regimen administration of methocarbamol were extracted and analyzed. The method consisted of enzyme hydrolysis followed by a one-step liquid-liquid extraction, separation on a reversed-phase (RP-18) column, and detection using an ultraviolet (UV) detector. The confirmation was carried out using a liquid chromatography-atmospheric pressure ionization-mass spectrometry (LC-API-MS) system. Maximum methocarhamol concentrations of 1498, 1734, 1547, and 2322 pg/mL in urine and 4.9, 1.7, and 3.6 pg/mL in serum were observed. The peak concentrations of the drug were detected 1-4 h (urine) and 10-60 min (serum) after administration to four horses. The method validation results and drug elimination profiles for both urine and serum are presented and discussed.
Introduction matography (HPLC) with ultraviolet (IN) and atmospheric pressure ionization-mass spectrometric (API-MS) detection for the separation, determination, and confirmation of methocarbamol.
Traditional techniques for detection of methocarbamol in biological samples include thin-layer chromatography (TLC) (5), carbon-14-1abeled drug use (3), spectrophotometric determination of the formaldehyde derivative of methocarbamol (6) , and HPLC with refractive index detection (7) . HPLC with IN and photodiode array detection (4, (8) (9) (10) (11) has been the method of choice recently for the detection of this drug in forensic toxicology.
This paper reports a rapid HPLC-UV method for the determination of methocarbamol in equine urine and serum following a simple one-step liquid-liquid extraction. The method validation results and drug elimination profiles for both urine and serum are presented and discussed. An LC-API-MS method was also developed for the confirmation of methocarbamol in biological systems.
Methocarbamol, 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate, is a muscle relaxant with effects occurring within approximately one half-hour of oral dosing. This drug is used in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasms, cramps, and dislocations (1) . The metabolism of methocarbamol in rats, dogs, and humans has been studied (2,3). Dealkylation, hydroxylation, and glucuronide and sulfate conjugations were determined to be the major metabolic pathways for this drug in these three species. Guaifenesin [3-(2-methoxyphenoxy)-1,2-propane-diol], a chemically and pharmacologically related derivative, was also found to be a rnetabolite of methocarbamol in horses (4) .
Methocarbamol has considerable potential for abuse in horse racing and has reportedly been used to allow unfit horses to remain in competition. In the course of investigations aimed at the detection of this drug in equine biological fluids, we examined the application of high-performance liquid chro-3 g oral (P.O.) via a stomach tube on the fifth day. Blood and urine samples were collected at various times up to 121 h (urine) and to 120 h (blood) after administration. Blood samples were centrifuged immediately after collection, and the serum was isolated. Urine and serum samples were frozen until analysis. 
Serum extraction
Serum sample (2 mL) was fortified with 10 IJg/mL mephenesin (internal standard), and the pH was adjusted to 14 with 2M sodium hydroxide. The sample was then extracted twice with 6 mL diethyl ether, and the organic layers were combined and dried under a dry stream of nitrogen. The residue was dissolved in 200 ~L methanol. A 20-pL volume of the solution was used for injection into the HPLC. For all four horses, two sets of blank (preadministration) serum (2 mL) were fortified with authentic methocarbamol at the concentrations of 0.5, 1, 5, 10, and 20 pg/mL plus 10 pg/mL internal standard and extracted by the previously described procedure. 
Urine extraction
Urine sample (5 mL) was fortified with either 200 IJg/mL (1-12 h postadministration samples) or 15 pg/mL (pre-and 14-121-h postadministration samples) of mephenesin as internal standard, and the pH was adjusted to 5 with 1 mL 2M sodium acetate solution (pH 5). The sample was then hydmlyzed by the addition of 100 I~L [3-glucuronidase from
Helix pomatia (89400 units [3-glucuronidase/mL) and incubation at 37~ overnight. After cooling, the sample was washed with 8 mL diethyl ether, and the organic layer was discarded. The pH was then adjusted to 14 with 25% sodium hydroxide and extracted twice with 8 IJL diethyl ether. The organic layers were combined and dried under a dry stream of nitrogen. The residue was reconstituted in 200 tJL methanol. A 20-1~L volume of the solution was used for injection into the HPLC.
As the concentration of methocarbamol in the urine samples varied from low to very high, two sets of blank (pre-administration) urine (5 mL) were fortified as follows with authentic methocarbamol at two different concentration ranges for all four horses: low range (for pre-and 14-121-h postadministration samples) at 1, 5, 10, 20, 50, and 100 I~g/mL plus 15 I~g/mL internal standard and high range (for 1-12-h postadministration samples) at 100, 200, 600, 1000, 1500, 2000, and 2500 tJg/mL plus 200 IJg/mL internal standard.
HPLC-UV analysis
The chromatograph was a Millipore-Waters instrument (Milford, MA) equipped with a model 510 HPLC pump and a Waters 712 WISP autosampler. A Spectra-Physics (San Jose, CA) 100 variable wavelength UV detector was used for the detection at 280 nm. A prepacked analytical column (250 x 4 ram, 7-1Jm particle size) of LiChrospher 100 RP-18 (Merck, Darmstadt, Germany) protected by a 4 x 4-ram guard cartridge with the same packing was used for the analysis at ambient temperature. The elution was isocratic using 1% aqueous acetic acid-acetonitrile (80:20) at a flow rate of 1 mL/min.
LC-MS analysis
The chromatographic system consisted of a Millipore-Waters instrument equipped with a model 600 E rnultisolvent delivery pump. The column and elution profile were as described previously.
The MS analysis was performed using a triple quadrupole mass spectrometer (API III LC-MS-MS system, PE Sciex, Thornhill, ON, Canada) with a heated nebulizer interface. The pressure and temperature for the heated nebulizer were 75 psi and 400~ respectively. The auxiliary nitrogen flow rate was 1.4 L/rain, and the nitrogen-curtain gas flow was 1.2 L/rain. The positive mode ionization was performed by applying a discharge current of 3 pamps. The MS-MS spectra were obtained with the collision-induced dissociation (CID) technique in the second quadrupole using argon as the collision gas with a thickness of 485 x 101~-rnolecules/crn 2. The dwell time was 5 ms, mass defect was 55, and step size was I arnu. 
Results and Discussion
The urine and serum samples were extracted by a straightforward liquid-liquid extraction procedure (following enzyme hydrolysis for urine). Methocarbamol was then identified by the comparison of the HPLC retention time with that of a reference standard and confirmed using mass spectra obtained by a LC-API-MS technique. The concentrations of methocarbamol in the administration urine and serum samples were calculated based on peak-area measurements and an internal standard calibration procedure.
Urine
The administration urine samples along with the spiked samples showed two peaks in their HPLC chrornatograms, a methocarbamol peak (11.8 rain) and a small peak at a shorter retention time (9.1 rain) that was identified as guaifenesin (a known degradation product of methocarbarnol). Figure 1 shows a typical HPLC-UV chrornatogram obtained for an administration urine sample. The standard methocarbarnol, however, showed a single peak, which indicated that the degradation of rnethocarbamol occurred in the extraction stage or was a result of the matrix effect.
Methocarbamol concentrations in administration urine samples of four horses analyzed are listed in Table I Figure 2 shows the variation of methocarbarnol concentration with time in urine samples from all four horses following administration of the drug. The drug was detected up to the last sample collected (121 h) at concentrations greater than 0.7 lJg/mL (limit of detection, LOD) in all horses with the exception of a 79-h postadrninistration sample from horse K, which was less than the LOD. The average urine concentrations of rnethocarbarnol in four horses at different postadministration times are listed in Table I where 1614 pg/mL is the maximum drug concentration 2 h after the administration.
Serum
The serum samples also showed two peaks in their chromatograrns, rnethocarbamol and guaifenesin, as observed in the administration urine. Methocarbamol concentrations in serum samples of all horses are listed in calibration curves used for the determination of methocarbamol concentration in serum samples of individual horses were linear with correlation coefficients of 0.9999 (horses D and N) and 0.9998 (horses K and L). The peak concentration of the drug in the serum samples occurred 10 rain after the administration of the drug for horse D, 40 rain for horse N, and 60 rain for horses K and L. However, this level varied from 4.9 pg/mL (horse D), to 1.7 IJg/mL (horses N and K), to 3.6 IJg/mL for horse L. Figure 3 shows the methocarbamol elimination profile in serum for horses D, K, L, and N. The drug was detected up to 6 h (horses D, L, and N) and 3 h for horse K at concentrations greater than 0.2 pg/mL (LOD). The average serum concentrations of methocarbamol (four horses) at different postadministration times are listed in Table II where 2.5 Dg/mL is the maximum drug concentration 40-60 rain after the drug administration.
Method validation
The HPLC-UV method used for the determination of methocarbamol in urine samples was validated before use. The vali-
Time (h) Figure 3 . Methocarbamol elimination profiles in serum of four horses after regimen administration of Robaxin.
dation requires a demonstration of the sensitivity, calibration linearity, precision, and accuracy of the method. The intraday precision (repeatability) and interday precision (reproducibility) were determined. A plot of concentration (0.2-2500 pg/mL) versus peak area in duplicate resulted in a linear curve, which indicated that the detection was linear up to the highest concentration analyzed (2500 pg/mL) with a correlation coefficient of 0.9996. For the LOD and limit of quantitation (LOQ) the values ofyB + 3sn and Yn + 10sB, respectively were used where the calculated intercept of the regression line can be used as an estimate of YB and sn is the standard deviation of the signal (noise) at the rnethocarbamol retention time in the blank urine (n = 8). The calculated LODs were 0.70 pg/mL (urine) and 0.20 IJg/mL (serum), and the LOQs were 1.09 and 0.55 pg/mL, respectively. In order to assess the intraday precision of the method, we analyzed urine samples fortified with 4, 5, and 6 I~g/mL methocarbamol (seven replicates). The interday precision was calculated by repeating the same experiment for three consecutive days. The results are given in Table III . The accuracy of the method calculated for urine samples fortified at 4 and 6 pg/mL was 104% and 99.3% (n = 3) with percent relative standard deviations (%RSD) of 7.1 and 3.4, respectively.
LC-MS
Although HPLC-UV is a valuable technique for screening methocarbamol in equine urine and serum, the detection is solely based on comparison of the retention time of the drug with that of a standard reference. An LC-MS method, therefore, was used to confirm the methocarbamol detection in administration urine and serum. The application of a mass spectrometer as a detector for HPLC provided structural information that confirmed the identification, especially in complex matrices.
The heated-nebulizer interface, which was used for coupling the HPLC and API-MS in this work, used ionization by a corona discharge formed at the tip of a needle. The effluent from the HPLC column was converted into a fine, warm mist and flowed into the reaction region, where the sample was ionized by charge transfer from the primary reagent ions created from the solvent vapor by corona discharge. The precursor ion of interest (selected by the first quadrupole) then undergoes gas (argon) collisions in the second quadrupole, and the product ions passed through a third quadrupole and were detected (12) . The positive product-ion mass spectrum of the methocarbamol reference standard ( Figure 4) showed a major ion at m/z 242, corresponding to M+I with a few fragments of which ion 118 was the base peak. The ion at m/z 224 indicated the loss of a H20 molecule. The spectrum may be partially rationalized by the fragmentation shown in Figure 4 .
Analysis of serum and urine samples using this technique yielded similar mass spectral data, thereby confirming the presence of methocarbamol in these samples.
Conclusion
Analysis of methocarbamol by HPLC-UV provides a rapid and sensitive method for the determination of this drug in equine serum and urine samples. Detection limits and recoveries obtained for methocarbamol are satisfactory for the determination of low levels of this drug in equine biological fluids. The peak concentrations of the drug in four horses studied varied from 1498 to 2322 pg.mL in urine (1-4 h postadministration) and 1.7 to 4.9 ~g/mL in serum (10-60 min postadministration). The data obtained from the method validation showed acceptable intra-and interday precision and accuracy for the method.
The application of LC-API-MS-MS technique provided structural information that confirmed the authenticity of the methocarbamol peak detected in the urine and serum samples.
